Fig. 1.

Ectopic bone induction at four weeks by SVAK-12. There was a dose-dependent increase in the rhBMP-2-induced bone formation as evidenced by the increasing mean bone scores with increasing doses of SVAK-12. Significant differences compared with implants treated with the vehicle (DMSO)—i.e., the control group—were found at the 100, 250, and 500-μg doses of SVAK-12 (*p < 0.02). Typical radiographs of the ectopic ossicles in the various treatment groups are shown below their respective bone scores. The radiopaque areas of the SVAK-12-treated groups (25, 50, 100, 250, 500, and 750 μg/100 μL) were larger and more dense than those in the control group.